S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
Log in
NASDAQ:GALT

Galectin Therapeutics Stock Forecast, Price & News

$2.75
+0.22 (+8.70 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.50
Now: $2.75
$2.80
50-Day Range
$2.56
MA: $2.79
$3.08
52-Week Range
$1.50
Now: $2.75
$4.50
Volume278,916 shs
Average Volume217,660 shs
Market Capitalization$156.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Read More
Galectin Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.04 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.76 per share

Profitability

Net Income$-13,290,000.00

Miscellaneous

Employees6
Market Cap$156.87 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$2.75
+0.22 (+8.70 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

How has Galectin Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Galectin Therapeutics' stock was trading at $1.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GALT stock has increased by 38.2% and is now trading at $2.75.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Galectin Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Galectin Therapeutics
.

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Galectin Therapeutics
.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its quarterly earnings results on Monday, August, 10th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.04.
View Galectin Therapeutics' earnings history
.

What price target have analysts set for GALT?

2 analysts have issued 1-year target prices for Galectin Therapeutics' shares. Their forecasts range from $4.00 to $12.00. On average, they expect Galectin Therapeutics' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 190.9% from the stock's current price.
View analysts' price targets for Galectin Therapeutics
.

Who are some of Galectin Therapeutics' key competitors?

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the following people:
  • Dr. Harold H. Shlevin, Pres & CEO (Age 69)
  • Mr. Jack W. Callicutt, CFO & Sec. (Age 52)
  • Robert Tritt, Gen. Counsel
  • Dr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)
  • Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49)

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Advisor Group Holdings Inc. (1.77%), Nuveen Asset Management LLC (0.32%), Goldman Sachs Group Inc. (0.04%), Vivaldi Capital Management LLC (0.03%), UBS Group AG (0.02%) and Two Sigma Advisers LP (0.02%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Jack W Callicutt, Kary Eldred, Kevin D Freeman, Marc Rubin and Richard E Uihlein.
View institutional ownership trends for Galectin Therapeutics
.

Which major investors are selling Galectin Therapeutics stock?

GALT stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Galectin Therapeutics
.

Which major investors are buying Galectin Therapeutics stock?

GALT stock was purchased by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Nuveen Asset Management LLC, Two Sigma Advisers LP, Bank of America Corp DE, Vivaldi Capital Management LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Galectin Therapeutics stock in the last two years include Jack W Callicutt, Kary Eldred, Kevin D Freeman, and Richard E Uihlein.
View insider buying and selling activity for Galectin Therapeutics
.

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $2.75.

How big of a company is Galectin Therapeutics?

Galectin Therapeutics has a market capitalization of $156.87 million. The company earns $-13,290,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe.

What is Galectin Therapeutics' official website?

The official website for Galectin Therapeutics is www.galectintherapeutics.com.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.